Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$47.79 USD
-3.30 (-6.46%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $47.71 -0.08 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Praxis Precision Medicines, Inc. has a market cap of $1.04B, which represents its share price of $51.09 multiplied by its outstanding shares number of 20.37M. As a small-cap company, PRAX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
PRAX 47.79 -3.30(-6.46%)
Will PRAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRAX
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
PRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ensign Group (ENSG) Q4 Earnings and Revenues Beat Estimates
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
Other News for PRAX
Praxis Precision Medicine (PRAX): HC Wainwright & Co. Raises Price Target | PRAX Stock News
PRAX Price Target Increased by H.C. Wainwright Following Positive Trial Results
Praxis Precision Medicines to Participate in Upcoming Fireside Chat | PRAX Stock News
Praxis Precision price target raised by $10 at H.C. Wainwright, here's why
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ...